Scott Mendel - 08 Jul 2025 Form 4 Insider Report for Quanterix Corp (QTRX)

Reporting relationship: Director
Issuer ticker: QTRX
Reported as of: 08 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2025, 20:39:15 UTC
Prior SEC filing: 21 May 2025
Next SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Keane, as Attorney-in-Fact

Key filing fact

Scott Mendel filed Form 4 for Quanterix Corp (QTRX) on 10 Jul 2025.

Key facts

This page summarizes Scott Mendel's Form 4 filing for Quanterix Corp (QTRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jul 2025, 20:39.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001515051 Primary reporting owner

Mendel Scott

Relationship: Director
Address: C/O QUANTERIX CORPORATION, 900 MIDDLESEX TURNPIKE, BILLERICA
Signature: /s/ Brian Keane, as Attorney-in-Fact
Signature date: 10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QTRX transaction

Common Stock

Award

Transaction value
Shares: +4,189
Change %
Price
Shares after: 4,189
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F1

QTRX transaction

Common Stock

Award

Transaction value: $0
Shares: +24,464
Change %: +584%
Price: $0.000000
Shares after: 28,653
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QTRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,758
Change %
Price: $0.000000
Shares after: 50,758
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,578
Exercise price: $6.54
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Received in exchange for 28,500 shares of Akoya Biosciences, Inc. ("Akoya") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Mr. Mendel received: (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share.

Footnote F2

Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028.

Footnote F3

Includes 24,464 restricted stock units.

Footnote F4

The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments.